Upsher-Smith

Upsher-Smith’s ophthalmology portfolio continues to expand with the launch of Cyclosporine Ophthalmic Emulsion 0.05%.

Learn more here:

Upsher-Smith Launches Generic Version of Restasis® (cyclosporine ophthalmic emulsion 0.05%) - Upsher-Smith Read this post on the Upsher-Smith website.

Tuberous sclerosis complex (TSC) is a lifelong genetic condition that can cause noncancerous tumors in the brain, kidneys, heart, lungs, and skin. Its effects vary widely and may include seizures and autism spectrum disorder (ASD) manifestations.

Although TSC is classified as a rare disease, the impact on the people and families living with it is anything but rare. It shapes daily routines, influences major decisions, and calls for remarkable resilience.

Today, the stories of those affected bring visibility to experiences that often go unseen. And, as a company that provides therapies for certain individuals living with TSC, Upsher-Smith stands with this community in raising awareness and supporting continued progress.

Our Upsher-Smith team was proud to attend Epilepsy Awareness Day at Disney World for the first time.

Connecting with the broader epilepsy community reminds us why we do what we do — to support patients, families, and advocates who inspire us every day. From meaningful conversations to small moments of joy at our booth, including helping young visitors try on their superhero capes, the day was filled with reminders of the strength and spirit of this community.

These moments matter. They reinforce our purpose and strengthen our commitment to those living with rare and serious neurological conditions. We’re grateful for the stories shared, the connections made, and the opportunity to stand alongside this incredible community.

Today we honor the nurses who bring skill, compassion, and unwavering dedication to patient care. Thank you for the essential role you play in strengthening our healthcare system!

A reminder that caring for our minds is just as important as caring for our bodies — and deserves attention all year long.

Upsher-Smith is pleased to share new digital resources designed to support individuals living with Duchenne muscular dystrophy and the families and clinicians who care for them.

Our KYMBEE™ (deflazacort) Tablets caregiver and healthcare professional websites offer practical guidance on treatment access, helpful tools for caregivers, prescribing resources for clinicians, and information about the Promise of Support® Program.

Designed with the Duchenne community in mind, these platforms strive to provide access to trusted information quickly and confidently.

Click here to learn more: https://bit.ly/42euVOs

SELECT IMPORTANT SAFETY INFORMATION

KYMBEE (deflazacort) Tablets are a prescription medicine used to treat Duchenne muscular dystrophy (DMD) in patients 5 years of age and older.

Do not take if you have had hypersensitivity, including allergic reactions, to deflazacort (the active ingredient in KYMBEE) or to any of the inactive ingredients in KYMBEE.

Please see additional safety information: https://bit.ly/4tewBU3

And full Prescribing information: https://bit.ly/4sVyGUh

Upsher-Smith has launched Ciprofloxacin [0.3%] and Dexamethasone [0.1%] Otic Suspension.

Learn more about our first prescription ear drop suspension and its availability by clicking below:

Upsher-Smith Launches Generic Version of Ciprodex® (ciprofloxacin 0.3% and dexamethasone 0.1%) Sterile Otic Suspension - Upsher-Smith Read this post on the Upsher-Smith website.

Honoring the physicians whose dedication drives progress in healthcare.

Your leadership and expertise make a profound impact on patients and communities. Today, we say thank you.